Xuanmao Jiao1, Min Wang2, Zhao Zhang2, Zhiping Li2, Dong Ni2, Anthony W Ashton2,3,4, Hsin-Yao Tang5, David W Speicher5, Richard G Pestell6,7,8. 1. Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA, 19096, USA. xuanmao.jiao@bblumberg.org. 2. Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA, 19096, USA. 3. Division of Perinatal Research, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, 2065, Australia. 4. Sydney Medical School Northern, University of Sydney, Sydney, NSW, 2006, Australia. 5. Wistar Institute, Philadelphia, PA, 19107, USA. 6. Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, 100 East Lancaster Avenue, LIMR R234, Wynnewood, PA, 19096, USA. richard.pestell@bblumberg.org. 7. Wistar Institute, Philadelphia, PA, 19107, USA. richard.pestell@bblumberg.org. 8. Xavier University School of Medicine, 1000 Woodbury Rd, Suite 109, Woodbury, NY, 11797, USA. richard.pestell@bblumberg.org.
Abstract
BACKGROUND: Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled receptor CCR5 was expressed in > 95% of TNBC samples. A humanized monoclonal antibody to CCR5 (leronlimab), used in the treatment of HIV-infected patients, has shown minimal side effects in large patient populations. METHODS: A humanized monoclonal antibody to CCR5, leronlimab, was used for the first time in tissue culture and in mice to determine binding characteristics to human breast cancer cells, intracellular signaling, and impact on (i) metastasis prevention and (ii) impact on established metastasis. RESULTS: Herein, leronlimab was shown to bind CCR5 in multiple breast cancer cell lines. Binding of leronlimab to CCR5 reduced ligand-induced Ca+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration. Leronlimab enhanced the BCa cell killing of the BCa chemotherapy reagent, doxorubicin. In xenografts conducted with Nu/Nu mice, leronlimab reduced lung metastasis of the TNBC cell line, MB-MDA-231, by > 98% at 6 weeks. Treatment with leronlimab reduced the metastatic tumor burden of established TNBC lung metastasis. CONCLUSIONS: The safety profile of leronlimab, together with strong preclinical evidence to both prevent and reduce established breast cancer metastasis herein, suggests studies of clinical efficacy may be warranted.
BACKGROUND: Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled receptor CCR5 was expressed in > 95% of TNBC samples. A humanized monoclonal antibody to CCR5 (leronlimab), used in the treatment of HIV-infected patients, has shown minimal side effects in large patient populations. METHODS: A humanized monoclonal antibody to CCR5, leronlimab, was used for the first time in tissue culture and in mice to determine binding characteristics to human breast cancer cells, intracellular signaling, and impact on (i) metastasis prevention and (ii) impact on established metastasis. RESULTS: Herein, leronlimab was shown to bind CCR5 in multiple breast cancer cell lines. Binding of leronlimab to CCR5 reduced ligand-induced Ca+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration. Leronlimab enhanced the BCa cell killing of the BCa chemotherapy reagent, doxorubicin. In xenografts conducted with Nu/Nu mice, leronlimab reduced lung metastasis of the TNBC cell line, MB-MDA-231, by > 98% at 6 weeks. Treatment with leronlimab reduced the metastatic tumor burden of established TNBC lung metastasis. CONCLUSIONS: The safety profile of leronlimab, together with strong preclinical evidence to both prevent and reduce established breast cancer metastasis herein, suggests studies of clinical efficacy may be warranted.
Entities:
Keywords:
Breast cancer; CCR5; Leronlimab; Metastasis
Authors: W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic Journal: J Virol Date: 1999-05 Impact factor: 5.103
Authors: Xuanmao Jiao; Marco A Velasco-Velázquez; Min Wang; Zhiping Li; Hallgeir Rui; Amy R Peck; James E Korkola; Xuelian Chen; Shaohua Xu; James B DuHadaway; Sandra Guerrero-Rodriguez; Sankar Addya; Daniela Sicoli; Zhaomei Mu; Gang Zhang; Andres Stucky; Xi Zhang; Massimo Cristofanilli; Alessandro Fatatis; Joe W Gray; Jiang F Zhong; George C Prendergast; Richard G Pestell Journal: Cancer Res Date: 2018-01-22 Impact factor: 12.701
Authors: Elham Azizi; Ambrose J Carr; George Plitas; Andrew E Cornish; Catherine Konopacki; Sandhya Prabhakaran; Juozas Nainys; Kenmin Wu; Vaidotas Kiseliovas; Manu Setty; Kristy Choi; Rachel M Fromme; Phuong Dao; Peter T McKenney; Ruby C Wasti; Krishna Kadaveru; Linas Mazutis; Alexander Y Rudensky; Dana Pe'er Journal: Cell Date: 2018-06-28 Impact factor: 41.582
Authors: Gerd Fätkenheuer; Mark Nelson; Adriano Lazzarin; Irina Konourina; Andy I M Hoepelman; Harry Lampiris; Bernard Hirschel; Pablo Tebas; François Raffi; Benoit Trottier; Nicholaos Bellos; Michael Saag; David A Cooper; Mike Westby; Margaret Tawadrous; John F Sullivan; Caroline Ridgway; Michael W Dunne; Steve Felstead; Howard Mayer; Elna van der Ryst Journal: N Engl J Med Date: 2008-10-02 Impact factor: 176.079
Authors: Tamara Lah Turnšek; Xuanmao Jiao; Metka Novak; Sriharsha Jammula; Gina Cicero; Anthony W Ashton; David Joyce; Richard G Pestell Journal: Int J Mol Sci Date: 2021-04-24 Impact factor: 5.923
Authors: Xuanmao Jiao; Lifeng Tian; Zhao Zhang; Joanna Balcerek; Andrew V Kossenkov; Mathew C Casimiro; Chenguang Wang; Yichuan Liu; Adam Ertel; Raymond E Soccio; Eric R Chen; Qin Liu; Anthony W Ashton; Wei Tong; Richard G Pestell Journal: Cancers (Basel) Date: 2021-04-30 Impact factor: 6.639
Authors: Xiao L Chang; Helen L Wu; Gabriela M Webb; Meenakshi Tiwary; Colette Hughes; Jason S Reed; Joseph Hwang; Courtney Waytashek; Carla Boyle; Cleiton Pessoa; Andrew W Sylwester; David Morrow; Karina Belica; Miranda Fischer; Scott Kelly; Nader Pourhassan; Rachele M Bochart; Jeremy Smedley; Christopher P Recknor; Scott G Hansen; Jonah B Sacha Journal: Front Immunol Date: 2021-11-19 Impact factor: 8.786